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Abstract
Human immunodeficiency virus (HIV) rapidly penetrates into the brain and establishes a 
persistent infection of macrophages/microglia. Activation of these cells by HIV results in the 
secretion of soluble factors that destabilize neuronal calcium homeostasis, encourage oxidative 
stress and result in neural damage. This damage is thought to underlie the cognitive-motor 
dysfunction that develops in many HIV-infected patients. Studies have suggested that 
neurotrophins may protect neurons from the toxic effects of HIV-associated proteins. To better 
understand the pathogenic mechanisms and the neuroprotective potential of neurotrophin ligands, 
we evaluated neuronal damage, calcium homeostasis and mitochondrial functions after exposure 
of cultured rat neurons directly to HIV gp120 or to conditioned medium from human monocyte-
derived macrophages treated with gp120. We then assessed the ability of a new non-peptide p75 
neurotrophin receptor ligand, LM11A-31, to stabilize calcium homeostasis and prevent the 
development of pathology. Each toxic challenge resulted in a delayed accumulation of 
intracellular calcium coupled to a decrease in the rate of calcium clearance from the cell. The 
delayed calcium accumulation correlated with the development of focal dendritic swellings 
(beading), cytoskeletal damage and impaired movement of mitochondria. Addition of LM11A-31 
to the cultures at nanomolar concentrations eliminated cell death, significantly reduced the 
pathology, suppressed the delayed accumulation of calcium and restored mitochondrial 
movements. The potent neuroprotection and the stabilization of calcium homeostasis indicate that 
LM11A-31 may have excellent potential for the treatment of HIV-associated neurodegeneration.
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Introduction
Human immunodeficiency virus (HIV) rapidly enters the central nervous system (CNS) 
where it productively infects macrophages and microglia. The presence of virus is often 
associated with the gradual development of a range of cognitive-motor deficits. Although 
combination antiretroviral therapy (CART) has decreased the severity of neurological 
symptoms, CNS disease continues to progress in HIV-infected patients (Gongvatana et al., 
2013; Heaton et al., 2011) and evolve into different types of pathology(Brew, 2004; 
Gongvatana et al., 2013; Heaton et al., 2011; Langford et al., 2003; Masliah et al., 1997; 
Sacktor et al., 2002). Interventions are needed to suppress neuropathogenesis which, if 
unchecked, is expected to support an increasing neurological disease burden.
Soluble factors released in response to inflammatory activation of macrophages and 
microglia by the virus and viral proteins are thought to contribute substantially to the 
development of HIV-associated neurological deficits(Giulian et al., 1990; Kaul et al., 2001; 
Lipton, 1992; Pulliam et al., 1991; Xiong et al., 2000; Zheng et al., 1999). In HIV-infected 
patients the abundance of activated macrophages/microglia in the CNS is one of the best 
correlates of the severity of CNS disease(Fischer-Smith et al., 2004; Glass et al., 1995). 
Although the identity of the macrophage-derived toxins and the specific mechanisms of 
neuropathogenesis are still being defined, facilitation of NMDA glutamate receptor activity, 
accumulation of excess intracellular calcium and oxidative stress have been implicated(Kaul 
et al., 2001; Turchan et al., 2003a). Abnormal increases in intracellular calcium in neurons, 
in particular, may be a common underlying feature of the neurotoxic processes(Pivovarova 
and Andrews, 2010). Partial neuroprotection has been seen for a wide range of antagonists 
that block increases in intracellular calcium(Bragg et al., 2002; Dreyer et al., 1990; Holden 
et al., 1999) and agents that decrease oxidative stress(Turchan et al., 2003b). Various 
strategies are being explored to suppress inflammation and protect neurons but no approach 
has thus far been shown to have strong neuroprotective efficacy in clinical trials.
A promising new therapeutic strategy for neuroprotection is suggested by a loss of 
neurotrophic support in the context of HIV infection. An analysis of proteins in 
cerebrospinal fluid (CSF) from HIV infected patients showed that several neurotrophins are 
increased in HIV-infected, cognitively normal patients but then decrease with increasing 
cognitive deficits suggesting that a loss of neurotrophin protection may contribute to 
pathogenesis(Meeker et al., 2005). In studies that model HIV neuropathogenesis, brain-
derived neurotrophic factor (BDNF) and nerve growth factor (NGF) protected neurons 
against Tat- (Ramirez et al., 2001) and gp120-mediated apoptosis(Bachis et al., 2006; 
Bachis and Mocchetti, 2005; Mocchetti and Bachis, 2004; Peruzzi et al., 2002). A large 
number of studies across many fields support the widespread protective and repair functions 
of the neurotrophins and has fostered considerable work on their therapeutic use. However, 
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these efforts have been limited by difficulties with stability, access to the CNS and side 
effects(Allen et al., 2013).
The recent development of a new class of neurotrophin ligands has made it possible to 
examine the efficacy of novel non-peptide compounds that modify neurotrophin receptor 
function. The prototype neurotrophin ligand for our studies, LM11A-31, is a small molecule 
selected to mimic the loop 1 region of NGF, a domain known to bind the p75 neurotrophin 
receptor (p75NTR)(Longo et al., 2007). This compound has been shown to have neurotrophic 
activity and promote Akt-1 signaling(Massa et al., 2006). The following studies examined 
the potential of LM11A-31 to protect cultured neurons from the damaging effects of HIV 
gp120 and macrophage-generated toxins.
Materials and Methods
Neural cultures
Neural cultures were prepared from the cortex/hippocampus of E17 rat fetuses. Pregnant 
female Long-Evans rats were lethally anesthetized with isoflurane and the uterus removed 
and placed in ice cold HEPES-buffered Hank’s balanced salt solution (HBSS). The brain 
was harvested from each fetus, rinsed three times in fresh sterile HBSS and the forebrain 
containing the cortex, hippocampus and basal ganglia transferred to a 15 ml tube containing 
calcium-magnesium free HBSS (CMF-HBSS), 1.25 U/ml dispase II + 2 U/ml DNase I. 
After incubation for 25–30 min at 37° C the cells were gently dissociated by several rounds 
of trituration and seeded into poly-D-lysine-coated culture dishes at a density of 50,000 – 
100,000 cells/cm2 for toxicity analysis or 20,000 cells/cm2 on poly-D-lysine-treated 
coverslips for imaging. The resulting cultures were typically >90% neurons at 6 days in 
culture (average value for representative cultures was 96 ± 2% neurons). Cultures were fed 
with Minimum Essential Medium (MEM) with glutamine, 10% fetal bovine serum and 20 
μg/ml gentamicin, 50% exchange, three times per week. Cells were allowed to grow at least 
6 days in vitro, at which time they show extensive synaptophysin immunoreactivity and 
excellent responses to gp120, macrophage-conditioned medium and glutamate receptor 
agonists.
Initially, a challenge with the HIV envelope protein gp120 (200 pM) was selected to assess 
neuroprotection due to previously demonstrated effects on neurotrophins and the large body 
of data available for the toxic effects of this protein. To determine the most effective 
stimulus and the earliest changes associated with neural damage, different strains of gp120 
were compared using intracellular calcium accumulation and cell death as endpoints. This 
comparison helped to rule out the possibility that toxicity and protective effects may be 
unique to particular subtypes of gp120. The effects of the gp120 were also contrasted to the 
toxic effects previously seen with CSF from HIV-infected patients(Meeker et al., 2005) to 
determine if similar toxic effects were present. In addition, gp120 was applied to monocyte-
derived macrophages with subsequent testing of the conditioned medium on neural cultures. 
A direct comparison of the toxicity of the conditioned medium to direct application of gp120 
showed that the conditioned medium produced similar effects but was much more potent. 
Thus, the neuroprotective effects of LM11A-31 in the sensitive calcium assays were 
assessed using the more potent conditioned medium.
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Sources and types of gp120
Since both CXCR4- and CCR5-preferring subtypes of gp120 have been shown to be toxic to 
neurons but may have slightly different actions(Kaul et al., 2007), we compared the 
pathogenic effects of each subtype to determine if there was a common effect leading to 
neural dysfunction. Four subtypes of gp120 were obtained from the AIDS Reference 
Reagent Program. Two subtypes, gp120IIIB and gp120MN represented CXCR4-preferring 
subtypes and two subtypes, gp120BaL and gp120SF162 represented CCR5-preferring 
subtypes. A separate supply of full length, glycosylated gp120LAV (sequence similar to 
gp120IIIB) was also obtained from Protein Sciences (Meriden, CT). The gp120IIIB and 
gp120LAV both yielded similar effects. A challenge concentration of 200 pM was chosen 
based on previous work(Digicaylioglu et al., 2004; Dreyer et al., 1990; Garden et al., 2002; 
Kaul and Lipton, 1999; Meucci and Miller, 1996). To avoid multiple freeze-thaw cycles, a 
100X stock was prepared in an artificial CSF (aCSF, concentrations in mM: NaCl 137, KCl 
5.0, CaCl2 2.3, MgCl2 1.3, glucose 20, HEPES 10, adjusted to pH 7.4 with NaOH), 
aliquoted and stored frozen until use. In some experiments, lipopolysacchraride (LPS 0.1 
μg/ml) and rat interferon-γ (INF, 20 U/ml) were applied to the cultures to provide a strong 
positive control for inflammatory damage.
Conditioned medium from human monocyte-derived macrophages (hMDM)
Human peripheral blood mononuclear cells (PBMCs) from healthy donors were purchased 
from the New York Blood Center (Long Island City, NY). Research was approved by the 
center prior to acquisition and the blood was shipped with no identifiers of any kind. 
Approximately 108 PBMCs were obtained, washed and cultured in DMEM + 10% FBS in 6-
well plates on low adhesion plastic. Monocytes were allowed to adhere for a period of 5–7 
days after which they were transferred to DMEM containing 15 ng/ml recombinant human 
granulocyte-macrophage colony stimulating factor (GM-CSF, R&D Systems, Minneapolis, 
MN) and differentiated for an additional 5 days. After differentiation the macrophages were 
returned to DMEM + 10% fetal bovine serum. These mature macrophages were then washed 
and treated with 200 pM gp120 in 2 mls DMEM + 1% FBS per well (without GM-CSF) for 
a period of 3 days. The resulting medium was collected, aliquoted and stored at −80°. 
Cultures treated identically but with no gp120 stimulation were used as controls.
For MDM-neuron co-cultures, rat MDM were isolated from 14–16 mls of blood and 
cultured in a similar fashion. Cells were harvested from the low adhesion plates in calcium-
magnesium free Hank’s Balanced Salt Solution (CMF-HBSS) at 4° C (~20–30 min), 
centrifuged and the pellet re-suspended in aCSF at a density of 5000 cells/ml at room 
temperature. The cells were then seeded onto the neuronal cultures at a density of 
approximately 1000 cells/cm2 (4% of the neuron density) to observe direct interactions of 
macrophages with neurons.
Measurement of cell death
To assess cell death in response to a challenge, the live culture was stained by adding 1 μM 
ethidium homodimer to the medium for a period of 20 min followed by washing and fixation 
in 70% ethanol. Nuclei of dead cells show an intense red fluorescence. In some experiments 
nuclei were stained with 0.5–1 μM bisbenzimide (Hoechst 33258) or Sytox green for double 
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labeling studies. Counting of dead cells was accomplished by systematically sampling the 
left, right, top, bottom and middle of each well at an image magnification of 195X. The five 
readings were then averaged to provide a single value for each well. Metamorph Image 
Analysis software (Molecular Devices, Union City, CA) was used to identify stained nuclei 
using brightness and object size discriminators. The total number of objects that met the 
criteria for a stained nucleus was automatically counted. This procedure provided a 
relatively unbiased estimate of the stained nuclei for approximately 18% of the total surface 
of each well of a 96 well plate, representing approximately 2800 total neurons.
Immunocytochemistry
Neurons were identified by microtubule-associated protein-2 (MAP-2) immunostaining. 
Cells were fixed in ice cold 97% methanol, 3% acetic for 10 min at room temperature and 
washed in 0.01 M phosphate-buffered saline (PBS, 3×5 min). After incubation in blocking 
buffer containing 3% normal goat serum in 0.01 M PBS for 60 min polyclonal rabbit anti-
MAP-2 (Chemicon/Millipore, Bilerica, MA) was applied at a dilution of 1:500 in blocking 
buffer and incubated overnight at 4°C. The cells were washed three times in PBS and 
incubated in biotinylated goat anti-rabbit at 1:500 for 1 h at room temp or goat anti-rabbit 
Alexa488 (1:500) or mouse anti-rabbit Alexa568 (1:500). The cells were washed three times 
in PBS. Cells with the biotinylated secondary antibody were incubated for 1 h at room temp 
in avidin-Alexa488 (1:500, Molecular Probes/Invitrogen, Carlsbad, CA) and then washed 
3×5 min. Nuclei were counterstained with bisbenzimide (0.5 μM, Sigma Corp, St Louis, 
MO) for 20 min in PBS, washed 2×5 min and the coverslips were mounted onto slides with 
Fluoromount (Southern Biotech, Birmingham AL). A similar protocol was followed for 
staining of phospho-Akt (pAkt) and phospho-cyclic AMP response element binding protein 
(pCREB).
Staining was examined with an Olympus IMT-2 or IX71 inverted microscope and quantified 
with digital imaging and Metamorph (Molecular Devices, Downingtown, PA) imaging 
software. Fluorescence brightness intensity was measured at magnifications of 334X and 
674X and the density of neurons and processes was quantified using the threshold and 
intensity functions. Images were collected from pre-determined regions of the coverslip and 
analyzed by an individual unaware of the treatment conditions. The total area occupied by 
MAP-2 immunoreactive cell bodies and processes was measured and expressed as a 
percentage of the entire field and the average pAkt and pCREB stain intensity for the 
MAP-2 positive neurons was measured. Data was collected from individual neurons at high 
magnification and the population distributions and average intensity of the neurons 
compared across conditions. Intensity values were corrected for background measured in 
regions that did not contain cells. Astrocytes were also weakly positive for pAkt and pCREB 
but were not measured (MAP-2 negative).
LM11A-31: a non-peptide neurotrophin ligand
The compound LM11A-31 was initially identified by Drs. Longo and Massa using a virtual 
screen of a small molecule library to identify compounds mimicking the spatial and physical 
chemical features of the loop 1 region of NGF, a domain known to bind to p75NTR (Massa 
et al., 2002). Subsequent screening of compounds showed LM11A-31 to have neurotrophic 
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activity, high affinity for p75NTR, and the ability to activate downstream signaling via PI3 
kinase and Akt(Massa et al., 2002; Massa et al., 2006) with no direct actions on the nerve 
growth factor receptor, TrkA or the brain-derived neurotrophic factor receptor, TrkB. 
LM11A-31, has potent neuroprotective properties under conditions of serum starvation with 
EC50 values of 200–300 pM and a maximally effective concentration of 5–100 nM in 
various assays(Massa et al., 2006; Yang et al., 2008).
Calcium imaging
Neuronal cultures were washed in HEPES-buffered artificial CSF (aCSF, concentrations in 
mM: NaCl 137, KCl 5.0, CaCl2 2.3, MgCl2 1.3, glucose 20, HEPES 10, adjusted to pH 7.4 
with NaOH) and pre-loaded with the calcium indicator, Fluo-3 AM or Fluo-4 AM using the 
Molecular Probes Fluo-4 NW Calcium Assay Kit (Molecular Probes/Invitrogen, Eugene, 
OR) at a 1:4 dilution. After 30 minutes, cultures were washed in aCSF and 18 mm 
coverslips mounted in a specialized stage for imaging (Warner Instruments, Hamden, CT). 
Images were captured on an Olympus IX71 inverted microscope at a temperature of 25° 
which provided stable background activity for at least 2 hrs. LM11A-31 was added to the 
coverslips in the chamber 10 min prior to the challenge. The cells were challenged with 200 
pM gp120 final concentration or conditioned medium from hMDM treated for 3 days with 
200 pM gp120. The toxic challenge was added in a volume of 80 μl to 320 μl in the chamber 
to provide a 1:5 dilution of the stock. Time lapse digital images were captured automatically 
by the Metamorph System (Molecular Devices, Union City, CA). Three pre-stimulation 
measurements were taken to establish basal levels of fluorescence at the beginning of each 
experiment. Acute changes in calcium were measured at 0.1 min intervals for 6 min. 
Delayed changes in calcium were measured at 1 min intervals for at least an additional 60 
min. The increase in fluorescence intensity (free calcium) within each cell was then 
measured relative to the baseline measurements to correct for cell to cell differences in dye 
loading and intrinsic fluorescence. Control cultures were stimulated with vehicle or control 
medium (medium from same hMDM cultures prior to the challenge with gp120) in the same 
fashion to establish normal baseline calcium activity as well as any intrinsic toxic activity 
from the hMDM cultures.
Imaging of mitochondria with JC-1 and TMRM
To measure changes in the mitochondrial membrane potential, neural cultures were loaded 
with JC-1 dye (Molecular Probes/Invitrogen) at a concentration of 3 μM in complete 
medium for 30 min at 36°. Cells were washed with aCSF, placed in an imaging chamber and 
challenged with a 1:5 dilution of toxic human CSF previously shown to cause substantial 
calcium dysregulation. The red and green fluorescence was measured in individual 
mitochondria with narrow bandpass filters at 6–12 minute intervals over a period of 96 min. 
The average green:red ratio was calculated and plotted over time. Polarized healthy 
mitochondria have a low green:red ratio and the ratio increases with depolarization. Fluo-3 
fluorescence, reflecting intracellular calcium, was measured in parallel cultures under the 
same conditions and plotted over the same time period for a temporal comparison to changes 
in mitochondrial membrane potential.
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Experiments were also done using cells loaded with 10 nM tetramethlyrhodamine methyl 
ester (TMRM) to label mitochondria. TMRM was added to the cells for 10 min at the end of 
the 30 min loading period for the calcium indicator Fluo-4. Cells were washed in aCSF, and 
the mitochondria imaged. The cells were then challenged with conditioned medium from 
gp120-stimulated human MDM (1:5). Fluorescence of the calcium indicator was measured 
over time. Regions of dendrites where swelling occurred were then compared to the location 
of mitochondria to determine if there was a relationship between the presence of 
mitochondria and damage.
Mitochondria movements were tracked by labeling with 10 nM TMRM for 10 min followed 
by addition of the MCM challenge with or without drug. Time lapse images were collected 
over a period of 30 min. Imaging was initiated in some studies immediately after stimulation 
with macrophage conditioned medium while in other studies the cells were pre-incubated for 
period of 30 min to allow the development of pathology. No changes in TMRM 
fluorescence were seen as a result of immediate MCM treatment or after incubation for 30 
min verifying that there were no acute effects on the mitochondrial membrane potential.
Statistics
Results are presented as the mean ± sem unless otherwise indicated. Parametric statistics, 
ANOVA for multiple comparisons and t-test for single comparisons, were calculated using 
Graphpad Prism software. In the case of multiple comparisons the ANOVA was followed by 
specific individual paired comparisons to correct for the multiple comparisons. In some 
cases t-tests were run on two comparisons without correction when there was a single main 
effect and a secondary comparison to validate stimulus effectiveness. A cutoff of 0.05 was 
accepted as significant. Estimates of calcium recovery rates were obtained from linear 
regression analysis of the log transformation of calcium (fluorescence) levels relative to the 
peak response. The probability of equal slopes was calculated from the individual regression 
lines.
Results
Comparison of the neurotoxic effects of gp120 and macrophage conditioned medium
To provide a stringent and valid test of the actions of our neurotrophin ligand we utilized 
several toxic challenges and pathological endpoints that mimic effects seen in HIV-infected 
humans. Since gp120 is a well characterized stimulus that produces neurotoxicity we 
initially evaluated interactions of LM11A-31 with gp120-induced neurotoxicity. Because 
subtypes of gp120 may have differential effects in neural cultures we compared the effects 
of both CXCR4-preferring (gp120IIIB, gp120MN) and CCR5-preferring (gp120BaL and 
gp120SF162) subtypes to identify the optimal challenge and to determine if there were 
notable differences between HIV subtypes in our paradigm. Neural cultures were treated 
with 200 pM gp120 and cell death measured at 24 h. Figure 1A illustrates the cell death seen 
with each subtype of gp120. All subtypes were toxic relative to vehicle controls and resulted 
in an average cell death ranging from 67.2 to 85.3 cells/mm2 versus 18.4 cells/mm2 for 
vehicle controls (all p values < 0.006 for gp120 vs. control). The relative extent of cell death 
for the gp120 treated cultures ranged from 5.1 ± 1.0% to 6.5 ± 0.5% of total neurons versus 
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1.4 ± 0.2% for control cultures. While the increases in cell death represented 3.6 – 4.6 fold 
increases over control values it is important to note that most neurons in the culture did not 
die under these conditions.
To evaluate the neuroprotective efficacy of LM11A-31, neural cultures were incubated as 
above with 200 pM gp120IIIB in the presence or absence of 10 nM LM11A-31. To provide a 
strong positive control, a separate set of cultures was treated with a potent inflammatory 
stimulus, lipopolysaccharide (LPS 0.1 μg/ml) + rat interferon-γ (INF, 20 U/ml). Under these 
conditions gp120 induced a 152% increase in cell death and the LPS + γ-interferon a 494% 
increase in cell death relative to vehicle treated controls (Figure 1B). Co-treatment with 10 
nM LM11A-31 completely reversed the cell death in both cases, resulting in less cell death 
than vehicle-treated controls.
Previous studies of CSF from HIV-infected patients had indicated that delayed calcium 
destabilization was an early and sensitive index of toxicity(Meeker et al., 2005). To 
determine if each gp120 subtype also caused similar changes in calcium homeostasis, we 
evaluated the direct effect of each of four subtypes of gp120 on neuronal intracellular 
calcium regulation and the response to a glutamate challenge. As illustrated in Figure 2A, a 
negligible or small acute rise in intracellular calcium was seen followed by a gradual 
accumulation starting at approximately 10–20 min. By 60 min, an average rise of 117.1 – 
155.0% (±7.6 – 13.1%) was seen relative to 4.8 ± 3.8% in vehicle controls. All subtypes of 
gp120 produced similar effects on intracellular calcium. In seven independent experiments, 
the percentage of cells showing a dysregulation of intracellular calcium during exposure to 
gp120 was 67.1 ± 5.3%. Thus, under these conditions most neurons are dysfunctional 
although few die as a result of the challenge (4–5%).
To evaluate the ability of neurons to clear a calcium load after exposure to gp120, mixed 
neural cultures were incubated with each type of gp120 for three days followed by an acute 
2 s challenge with 200 μM glutamate with rapid washout. The acute response to a pulse of 
glutamate, shown in Figure 2B, was increased in all cells treated with gp120 (271 – 445% 
increase above basal) relative to cells treated with vehicle (aCSF, 136.0% increase above 
basal). Although peak levels varied slightly, between gp120 subtypes, (gp120BaL 445.5 ± 
35.5%; gp120MN 404.0 ± 36.2%; gp120IIIB 280.0 ± 21.6%; and gp120SF162 271.3 ± 22.9%) 
the pattern was the same for each. The increase in the acute calcium response was paralleled 
by a decrease in the rate of recovery as seen previously for CSF from HIV-infected patients 
and feline cultures infected with FIV(Bragg et al., 2002; Meeker et al., 2005). The ratio of 
fluorescence values at each time point (F) to the peak calcium (Fpeak) was calculated and log 
transformed to determine the rate of recovery (slope). After a slight delay of 12–18 s, all 
gp120 treated cells showed slower calcium recovery rates relative to untreated cells (Figure 
2C). The mean recovery rate for control cells was 4.43% s−1 versus 0.89% s−1 (IIIB), 0.83% 
s−1 (SF162), 0.95% s−1 (BaL), and 1.10% s−1 (MN), representing 4- to 5-fold decreases in 
calcium clearance.
Since the increased acute calcium response to glutamate after exposure to gp120 could 
contribute to the changes seen in the clearance rate we compared calcium clearance rates in 
cells with similar calcium loads. When the acute responses to a 2 s pulse of glutamate in 
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gp120IIIB-treated cells was matched to control cells (Figure 2D), a delay in calcium recovery 
was still evident in the gp120-treated cells. The corresponding plot of the transformed data 
in Fig 2D (inset) illustrates that the rate of recovery was 5-fold less than control cells even 
with the same acute calcium burden.
Since the toxic effects of gp120 may be largely due to interactions with macrophages and 
microglia, we also treated human monocyte-derived macrophages (hMDM) with 200 pM 
gp120 for a period of three days and examined the effects of the secreted products on 
neuronal calcium homeostasis. Macrophage conditioned medium (MCM) was applied to 
cultures at dilutions of 1:20, 1:10, 1:5 and 1:2.5. A linear dose-response relationship was 
seen between the concentration of conditioned medium and neuronal calcium accumulation 
assessed at 40 min, the approximate midpoint of the delayed rise. Fluorescence increases 
ranged from 47.6 ± 12.0 fluorescence units at a 1:10 dilution to 196.4 ± 12.0 fluorescence 
units at a 1:2.5 dilution (not shown, all p’s<0.05). The MCM, at a dilution of 1:5, produced a 
delayed increase in intracellular calcium (Figure 3A) that was typically 2–3 fold greater that 
that seen with gp120 alone. However, in contrast to gp120 alone, a large acute calcium 
response was seen. The acute calcium increase recovered only partially before the 
development of the delayed increase. Similar patterns were seen with medium from hMDM 
treated with gp120IIIB or gp120BaL again indicating little strain difference in the generation 
of a toxic response from macrophages. Although not necessary or sufficient for the 
development of the late rise, the acute rise appeared to facilitate the delayed response. Since 
glutamate in the conditioned medium was a candidate for the cause of the acute calcium rise, 
we measured the concentration in the MCM. Glutamate was present in the conditioned 
medium at an average concentration of 4.1 ± 0.5 μM (n=5 separate experiments). In our 
assay, with a medium dilution of 1:5 the glutamate delivered to the cultures was, on average, 
0.82 μM. Stimulation of the cultures directly with 0.82 μM glutamate, shown in Figure 3B, 
produced a rapid calcium rise followed by complete recovery by 2 min and no significant 
long-term destabilization. Thus, glutamate in the medium contributes to the initial calcium 
burden but could not account for the destabilization of calcium homeostasis. It is important 
to note that the glutamate concentration in the medium was not static. Fresh medium 
contained 12.9 ± 0.11 μM glutamate which was rapidly reduced to a steady state value of 4 
μM with a t1/2 of 2.95 h.
To further verify the toxic activity of the macrophages under conditions that mimic in vivo 
interactions, rat MDM (rMDM) treated with either gp120IIIB or gp120BaL were seeded into 
normal neural cultures at a low density to evaluate local interactions between the rMDM and 
neurons. After 24 h, macrophages were observed next to neurons. Figure 4 A–C illustrates 
several images of MAP-2 stained neurons (green) from the same culture with various levels 
of damage. Healthy neurons were seen in regions with no rMDM (Figure 4A) while neurons 
in the vicinity of rMDM (red) showed damage ranging from early signs of beading (Figure 
4B) to severe dendritic swelling, perikaryon shrinkage and pruning of processes (Figure 4C). 
Unchallenged macrophages did not produce damage (not shown) and in some cases 
appeared to facilitate neuronal growth suggesting a beneficial influence in the absence of an 
inflammatory challenge.
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LM11A-31 protects neurons from the effects of macrophage-derived toxins
Since conditioned medium from macrophages treated with gp120 produced greater neuronal 
damage and a much more robust destabilization of calcium than gp120 alone, we evaluated 
the ability of LM11A-31 to protect neurons challenged with human MCM at a dilution of 
1:5 for 24 h. Total MAP-2 immunostaining was used to provide an index of changes in 
neuronal architecture. As illustrated in Figure 5, treatment of the cultures with MCM 
resulted in a 32.2% loss of MAP-2 immunoreactivity relative to untreated cultures or vehicle 
treated cultures (p=0.00013). The loss of MAP-2 stain in the presence of MCM was largely 
due to a decrease in the area occupied by MAP-2+ processes with an additional but smaller 
contribution from decreased staining of the neuronal cell bodies. Addition of 10 nM 
LM11A-31 to the culture medium 10 min prior to the MCM challenge totally prevented the 
loss of MAP-2 staining (p=0.0073 vs. MDM; 14% greater MAP-2 than control). An 
example of neurons damaged by MCM and the reversal of the damage by 2 nM and 10 nM 
LM11A-31 is shown in Figure 6A–C. The cultures treated with MCM showed dendritic 
beading and some pruning of processes (Figure 6A). Treatment with LM11A-31 at 2 nM 
partially restored the neuronal morphology (Figure 6B) and at 10 nM resulted in near-
normal, healthy-looking neurons with abundant processes (Figure 6C).
To determine if this neuroprotection might be due to the stabilization of intracellular calcium 
we measured acute and delayed calcium changes in response to MCM. As summarized in 
Figures 7 and 8, the addition of 10 nM LM11A-31 to the cultures 10 minutes prior to 
addition of the MCM (1:5) had no effect on the peak acute calcium rise but facilitated 
recovery and strongly suppressed the delayed calcium rise. An example of the acute and 
delayed changes in intracellular calcium following application of MCM (1:5) in the absence 
or presence of 10 nM LM11A-31 (MCM+LM11A-31) is illustrated in Figure 7A. In the 
absence of LM11A-31, the MCM induced a large rapid rise in calcium at 0.1 min, very little 
recovery (3 min) and a large delayed destabilization of calcium (60 min, movie S1). The 
delayed calcium destabilization was associated with the development of dendritic beading 
and swelling of the perikaryon. In contrast, delayed calcium accumulation and the 
accompanying damage were suppressed in the cultures pre-treated with LM11A-31 (Fig 7B, 
MCM+LM11A-31) with no effect on the acute calcium response (movie S2). Figure 7C 
illustrates, at higher magnification, the local calcium accumulation associated with neuritic 
beading. The average changes in intracellular calcium are illustrated in Figure 8A–C. 
Maximum recovery of calcium in the presence of LM11A-31 relative to aCSF was 91.6% at 
10 min versus 37.0% in the absence of the neurotrophin ligand. The delayed destabilization 
of calcium was reduced from a peak of 264 ± 16 fluorescence units in the cultures treated 
with MCM to 67 ± 7. The background calcium destabilization in aCSF treated cells was 5.0 
± 4.6. Because the MCM might contain small amounts of residual gp120, we stimulated the 
cultures with gp120IIIB at the maximum possible concentration in the medium under the 
same conditions. A very small acute response was seen followed by a small gradual rise in 
intracellular calcium to 64.9 units above baseline. In addition, removal of the gp120 by 
ultrafiltration at 100 kDa had no effect on the MCM-induced neuronal calcium response (not 
shown). Calcium recovery following the acute peak in neurons treated with the MCM plus 
LM11A-31 was 3.3 times faster than the recovery rate for neurons treated with MDM-
conditioned medium alone (Figure 8B). To evaluate whether astrocytes or neurons might 
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also generate soluble toxins in response to gp120, conditioned medium was prepared from 
mixed neural cultures in the same fashion. As illustrated in 8C, this medium stimulated an 
acute rise in calcium but failed to trigger a delayed destabilization and damage. 
Quantification of the extent of beading during the calcium runs is illustrated in Figure 8D. In 
each case, pre-stimulation images were used to correct for any pre-existing varicosities or 
artifacts. The images of the varicosities were digitally filtered by size to specifically identify 
beading of the processes and the number of varicosities was normalized to the number of 
neurons in the field to correct for any differences due to cell density. The extent of beading 
at the end of the calcium run was negligible for neurons treated with aCSF (0.016 ± 0.036 
varicosities/neuron) and slightly increased by exposure to MCM collected prior to treatment 
with gp120 (MCM control, 0.271 ± 0.026). Conditioned medium from macrophages treated 
with gp120 increased beading to an average of 2.668 ± 0.644 varicosities/neuron (p= 0.0021 
vs. MCM control). Co-treatment of neurons with MCM and 10 nM LM11A-31 resulted in a 
reduction of the beading to 0.158 ± 0.081 varicosities/neuron, a 95% reversal relative to 
MCM (p=0.023). In addition, if cultures were returned to complete medium with or without 
LM11A-31 just after the development of beading an almost full recovery was seen within 
24–48 h indicating that these early pathological changes were reversible.
LM11A-31 signaling and neuroprotection
To begin to understand the signaling events that might be responsible for the observed 
neuroprotection, we examined neuronal changes in MAP-2, phospho Akt (pAkt) and 
phosphoCREB (pCREB). Neurons were identified by the MAP-2 stain and the effects of 
MCM were examined after 4 h and 20 h exposure. Examples of the pAkt and MAP-2 stain 
at 20 h post challenge and the merged images are illustrated in Figure 9A–I. After 4 h in 
conditioned medium, we measured a 25.1% reduction in the total MAP-2 stain (Figure 9J). 
Co-treatment with LM11A-31 had no significant effect on the total MAP-2 stain at this time. 
However, after 20 h, the loss of MAP-2 (28.7%, Fig 9D) was significantly reversed by the 
LM11A-31 (Fig 9G) to a level greater than the normal control neurons (p<0.001, Fig 9J). 
This time-dependent reversal indicated that the restoration of MAP-2 by LM11A-31 was 
gradual.
We next examined neuronal expression of pAkt, a primary intermediate in protective 
neurotrophin signaling. Neurons were co-stained with pAkt (Fig 9A,D,G, 20 h) and MAP-2 
(Fig 9B,E,H, 20 h). At 4 h, pAkt was increased 135% in neurons in response to the MCM 
challenge suggesting that the neurons mount an early protective response (Figure 9K). This 
increase in pAkt was unaffected by co-treatment with LM11A-31 (140% above controls). At 
20 h into the challenge (Fig 9A–I), the neurons treated with MCM expressed pAkt at a level 
15.6% below control values (p=0.0019) whereas the neurons co-treated with LM11A-31 
maintained an average expression of pAkt at a level 69% above the untreated control 
neurons (p<0.0001) indicating an increased ability to sustain Akt signaling in the presence 
of LM11A-31. Since the stain for pAkt was not as distinctive as the other stains, these 
results were confirmed by Western blot of the entire culture (not shown) which paralleled 
the changes in Fig 9K. Phosphorylation of CREB is a major downstream effect that could 
mediate also protection. Total pCREB did not change significantly in MCM-treated neurons 
at 4 h in the presence or absence of LM11A-31. After 20h, total pCREB expression (Fig 
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10A,D,G) decreased in the cultures treated with MCM (Fig 9D,J). Addition of LM11A-31 
with the MCM (Fig 9G–I) significantly increased pCREB expression above the MCM 
treated cultures (p<0.0001, Fig 9J). Thus, the protective response of LM11A-31 was also 
associated with sustained pCREB expression.
Calcium, pathology and mitochondrial dysfunction
The earliest sign of pathology was the development of focal varicosities in the dendrites 
(beading). To better understand the temporal relationship between calcium changes and the 
development of pathology, we compared the development of focal swelling to local changes 
in dendrite intracellular calcium. An analysis of 140 swellings from 5 experiments revealed 
that 97.8% of these regions showed a calcium rise prior to the development of swelling. On 
average, the calcium rise preceded the development of swelling by 20.0 ± 1.0 min. The 
calcium response associated with swelling varied from cell to cell but generally fell into two 
categories illustrated in Figures 11A and 11B. Some processes showed small acute increases 
in calcium (fluorescence) followed by a rapid rise (Cell 40-1). The superimposed box 
(dashed lines) illustrates where the swelling of the process occurs. Other processes (Cell 
59-2) showed a steady, continuous rise in calcium.
Since the appearance of focal swelling has been linked in some studies to mitochondrial 
dysfunction(Greenwood et al., 2007), we also examined the temporal relationship between 
calcium accumulation, mitochondrial depolarization and beading. The time course of 
calcium destabilization and the loss of the mitochondrial membrane potential were tracked 
over time in cultures treated with a 1:5 dilution of HIV+ human CSF previously selected for 
toxic activity. Fluo-3 was used to track calcium changes and an increase in the JC-1 
green:red ratio was used to assess mitochondrial depolarization. To facilitate comparison, 
each curve was normalized to the maximum fluorescence (% of maximum signal) or the 
maximum change in the green:red ratio seen after depolarization of the mitochondria with 1 
μM FCCP. The average normalized responses, summarized in Figure 11C, showed a 
transient hyperpolarization of the mitochondria (decrease in the green:red ratio) followed by 
a depolarization. However, by the time mitochondrial depolarization began to change 
significantly from baseline, at 48 min, the destabilization of calcium had reached 92% of its 
maximum value. These data indicate that calcium dysregulation precedes the loss of the 
mitochondrial membrane potential and is likely to be a more proximal cause of neuronal 
dysfunction. Focal swelling, however, occurred in a time frame consistent with the onset of 
mitochondrial depolarization. We therefore asked if mitochondria were localized to the 
regions of swelling to determine if there was a direct relationship between the two. TMRM 
stained mitochondria (Fig 12B) were mapped along the length of selected dendrites with 
prominent beading (Fig 12A) and superimposed on the location of varicosities (Fig 12C). 
Location maps were constructed (Fig 12D) representing 549 swellings. Although examples 
of overlap were seen as illustrated in Fig 12D, swellings occurred in the apparent absence of 
mitochondria (arrow) and mitochondria were often not associated with swelling. On 
average, 47.6% of the swellings were associated with mitochondria indicating a lack of 
concordance between the mitochondria and swelling. However, mitochondria that were 
localized to swellings often had a condensed morphology and were occasionally seen in 
unusual circular configurations within the swelling (Fig 12C, arrow) suggesting a disruption 
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of normal structure and transport. Because TMRM is dependent on an intact mitochondrial 
membrane potential we reasoned that the visibility of the mitochondria might be lost if they 
depolarize within the swellings. When we fixed the cells and stained for the mitochondrial 
marker Tomm20 (Fig 12E, green) the proportion of swellings (MAP-2, red) with 
mitochondria based on the dendritic mapping analysis (Fig 12F) increased to 94.3%. 
Clusters of stained mitochondria were uniquely seen in the swellings (arrows) suggesting an 
accumulation of depolarized mitochondria.
MCM-induced alterations in the cytoskeleton
Staining of MCM-treated neurons for F-actin with Alexa488-phalloidin revealed a dense 
accumulation of F-actin masses within the swellings indicating a disruption of the 
cytoskeleton (Fig 13A, B). Dense accumulations of actin were also seen in growth cones 
(Fig 13D) as compared to control cultures (Fig 13C). Similar changes have been seen in 
models of Alzheimer disease where the pruning of synapses and dendrites were 
hypothesized to be due to a loss of microtubule transport functions(Shahpasand et al., 2012; 
Zempel and Mandelkow, 2012). Although the relationship between the actin cytoskeleton 
and microtubules is not clear both have been implicated in the movement of mitochondria 
and neurotrophin containing vesicles(Lazarov et al., 2007; Stokin et al., 2005). To determine 
if transport was impaired in our model, we labeled the mitochondria with TMRM and 
measured both the movements and mitochondrial fluorescence intensity (membrane 
potential) over time. Movement maps representing the velocity of sequential movements of 
50 randomly selected mitochondria from control cultures or cultures treated for 20 min with 
MCM are illustrated in Figs. 14A and B. A total of 1157 mitochondrial movements were 
measured in the control neurons and 864 movements in the neurons treated with MCM. 
Periods of rapid movement are illustrated by the spikes of activity for individual 6 s epochs. 
Rapid variation in the height of adjacent spikes illustrates the stop and go nature of the 
movements. Mitochondria in the control neurons had many more high velocity movements 
than the MCM treated cells. A comparison of the mean velocity in neurons treated with 
vehicle, MCM or MCM+LM11A-31, summarized from three independent experiments, is 
illustrated in Figure 14C. The average velocity of mitochondrial movement decreased by 
52.2% in the presence of MCM relative to control cells (p=0.0015)(movie S3). Addition of 
10 nM LM11A-31 to the medium reversed the deficit (p=0.0044 MDM+LM11A-31 vs. 
MDM) and restored the movement of the mitochondria to control values (movie S4). 
TMRM intensity, a measure of the mitochondrial membrane potential, showed little overall 
change in the MCM-treated cells (Fig. 12D). However, a small increase in TMRM intensity 
was seen in control cells and LM11A-31 treated cells relative to the MCM-treated cells 
(MCM slope = +0.01495% min−1 vs +0.03876% min−1 for control neurons, p<0.0001). 
After addition of LM11A-31 to the medium the TMRM intensities were not significantly 
different from controls, again indicating no effect on the mitochondrial membrane potential. 
Since the movement and function of mitochondria may be associated with fusion or fission 
events, we evaluated the size of individual mitochondria over time (Fig. 14E). All 
mitochondria showed a reduction in apparent size over time but no differences were seen 
across all conditions. As noted above, mitochondrial movements that could be localized to 
swellings revealed aberrant patterns of movement such as small, non-productive back and 
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forth movements or circular movements within the swelling reinforcing the idea that a loss 
of transport may underlie the development of pathology.
Discussion
Calcium deregulation is an early determinant of neural dysfunction
The results from these studies support the important role of altered intracellular calcium 
homeostasis in the early development of neural dysfunction in response to HIV. Addition of 
HIV+ CSF, gp120 or MCM to the neural cultures all disrupted long-term calcium 
homeostasis with MCM showing the most potent effects. Both CXCR4 and CCR5 preferring 
strains of gp120 produced toxic effects albeit with slightly different potencies as previously 
described(Kaul et al., 2007). In each case, the gp120 resulted in a destabilization of 
intracellular calcium that correlated with a decrease in the rate of intracellular calcium 
recovery. The high activity of MCM relative to other challenges reinforces the view that 
macrophages/microglia are a primary source of factors that produce neurotoxicity. In 
addition, the strong similarity between effects of MCM and CSF from HIV infected patients 
(Meeker et al., 2005; Meeker et al., 1999) indicates that similar conditions exist in vivo.
The delayed destabilization of calcium was apparent within 20 min and preceded the 
depolarization of mitochondria under the same conditions. The delayed calcium rise was 
often seen in the absence of a strong acute calcium response indicating that the neuronal 
dysfunction was not secondary to a strong initial accumulation of calcium. In addition, when 
the acute calcium rise in the MCM treated neurons was matched to control neurons the late 
destabilization was seen only for the MCM treated cells. This differs from excitotoxic 
models(Tymianski et al., 1993) where a large initial calcium rise driven by a high 
concentration of glutamate is thought to play major role in the late destabilization. A notable 
difference between the gp120 alone and MCM was the presence of an acute elevation of 
intracellular calcium with application of the conditioned medium, likely due to the presence 
of a low concentration of glutamate in the MCM. When we challenged the neurons with the 
same concentration of glutamate a large acute response was seen but it was not sufficient to 
produce delayed calcium destabilization and pathology. The decreased rate of calcium 
recovery seen in these experiments is consistent with previous studies showing that that the 
delayed destabilization of calcium correlates with the inability to remove calcium from the 
cytosol(Besancon et al., 2008; Bragg et al., 2002; Meeker et al., 2005). This deficit would be 
consistent with the gradual accumulation of intracellular calcium.
Calcium, actin and the regulation of mitochondrial movement
Calcium accumulation was closely followed by focal neuritic swelling (beading). Dendritic 
beading and synaptic pruning are common to a number of neurodegenerative 
conditions(Greenwood et al., 2007; Sanchez-Varo et al., 2012; Takeuchi et al., 2005) but 
little is known about the mechanisms that lead to this pathology. Mitochondrial dysfunction 
has been implicated in some studies(Greenwood et al., 2007). Although it was difficult to 
find mitochondria moving into regions of swellings in the live imaging experiments, 
immunostaining for the mitochondrial marker Tomm20 revealed the presence of 
mitochondria and in some cases an accumulation of mitochondria. These observations 
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suggested that, upon entering a swelling, mitochondria rapidly lose their membrane 
potential. The loss of mitochondrial function might then provoke focal swelling(Greenwood 
et al., 2007). However, the precise relationship between calcium dysregulation, the loss of 
transport and development of swellings is not known. While uncontrolled accumulation of 
calcium in our studies reflects an early deficit in neuronal function that may set the stage for 
subsequent degenerative changes, further work is needed to clearly identify the mechanistic 
link between calcium dysregulation and neuronal damage. Calcium-dependent changes in 
the cytoskeleton are a prominent possibility as suggested by the appearance of disorganized 
F-actin. There are strong similarities between the dendritic pathology seen in our studies and 
neuritic beading seen in early Alzheimer pathogenesis where a disruption of microtubule 
transport has also been implicated as an early deficit(Shah et al., 2009; Stokin et al., 2005). 
Calcium-mediated changes in the cytoskeleton may be common to both neurodegenerative 
processes. The essential role of calcium in morphological plasticity including control of 
spine morphology is well established(Ackermann and Matus, 2003; Bonhoeffer and Yuste, 
2002; Ciani and Salinas, 2008; Fortin et al., 2010; Oertner and Matus, 2005). Changes in 
actin that determine spine movements and shape are regulated by calcium in a fashion that is 
both concentration and duration dependent. For example, normal entry of calcium through 
NMDA receptors and voltage-gated calcium channels, necessary for LTP, suppresses actin 
turnover and stabilizes spines through actin polymerization(Ackermann and Matus, 2003; 
Oertner and Matus, 2005) yet, under excitotoxic conditions that induce high, prolonged 
levels of calcium, F actin and spine structure are lost within as little as five minutes(Oertner 
and Matus, 2005). Similar effects are likely to influence transport functions. Future studies 
are needed to firmly establish the relationship between calcium regulation and structural 
plasticity in response to inflammatory disease.
Although an understanding of the relationship between calcium, actin, microtubules and 
organelle transport is still evolving, several studies provide support for the role of actin in 
control of mitochondrial movements. Inhibition of actin polymerization by cytochalasin D 
decreased the number of mitochondria moving in axons and dendrites and induced focal 
aggregation of actin(Ligon and Steward, 2000). The formation of actin-cofilin aggregates 
interfered with mitochondrial movements and was associated with synaptic loss and 
decreased MAP-2 expression(Cichon et al., 2012). Loss of transport has also been linked in 
some studies to a reduction in neurotrophic support(Lazarov et al., 2007). Chada and 
Hollenbeck(Chada and Hollenbeck, 2004) showed that neurotrophins may provide 
localization signals since mitochondria accumulated in regions next to NGF coated beads. 
Recent studies of van den Berg and Hoogenraad (van den Berg and Hoogenraad, 2012) 
indicated that short final movements involved in docking and cargo binding may follow 
actin filaments by a process dependent on PI3K. Thus calcium and neurotrophin signaling 
may function in parallel to control mitochondrial movements through interactions with actin. 
The actin destabilizing effects of high concentrations of calcium are qualitatively similar to 
the effects of p75NTR activation which cause neurite and growth cone retraction through a 
mechanism that involves the sequential activation of RhoA, ROCK and LIM-kinase(Davies, 
2000; Lu et al., 2009; Yamashita et al., 1999). Thus, signaling interactions between calcium 
and neurotrophins are likely to play a role in the regulation of the cytoskeleton and transport 
(Getz, 2012; Higuchi et al., 2012; Watkins et al., 2012).
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LM11A-31 neuroprotection
The ability to control neurotrophin signaling has the potential to provide neuroprotection via 
a wide range of processes including control of actin-dependent processes(Adalbert et al., 
2007; Salehi et al., 2000). In Alzheimer disease models, deleterious effects on actin and loss 
of dendritic complexity may be facilitated by p75NTR and suppressed by TrkA (Berardi et 
al., 2007; Costantini et al., 2005). Pharmacological disruption of proNGF maturation to NGF 
shifts the signaling bias toward p75NTR and induces cholinergic degeneration and cognitive 
decline in rats(Allard et al., 2012). Importantly, early neuritic damage in 4–6 month-old AD 
PS1(M146L)/APP(751SL) mice that precedes synaptic and neuron loss is associated with 
cytoskeletal defects, actin-cofilin rods, autophagic vacuoles within axonal swellings and 
decreased expression of the transport motors kinesin-1 and dynein(Sanchez-Varo et al., 
2012). The similarities to the neuronal pathology seen in the current experiments suggest a 
common neurodegenerative mechanism that could be restored by intervention with 
neurotrophin ligands.
The strong neuroprotective efficacy of the neurotrophin ligand, LM11A-31, seen in our 
studies indicates that regulation of p75NTR function can have potent therapeutic utility. 
These protective effects are consistent with the neuroprotective efficacy seen in other model 
systems where LM11A-31 has been shown to protect neurons in vitro against the toxic 
effects of amyloid-β1–42 aggregates(Yang et al., 2008) and the apoptotic effects of pro-nerve 
growth factor(Massa et al., 2006). Studies examining the mechanism of action of LM11A-31 
have shown PI3K-dependent activation of Akt-1 and NFκB(Massa et al., 2006). 
Downstream inhibition of GSK-3β, calpain/CDK5 and c-Jun activation and the preservation 
of CREB phosphorylation may contribute to the beneficial effects of this ligand(Yang et al., 
2008). In our studies, it is notable that the restoration of MAP-2 stained architecture 
followed the early appearance of damage, highlighting the reversibility of the deficits. The 
restorative effects may be due in part to the sustained activation of pAkt and pCREB in 
neurons treated with LM11A-31. The relatively rapid stabilization of calcium by LM11A-31 
early in the pathogenic cascade may also contribute independently to the high 
neuroprotective potency of LM11A-31. By preventing the corresponding disruption of actin, 
the transport of mitochondria is preserved (and possibly other organelles and molecules). 
Although more work is needed to better understand the precise mechanisms of protection by 
LM11A-31, it is clear that novel neurotrophin ligands have unique and potent therapeutic 
actions that may target the earliest stages of neurodegeneration.
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Highlights
• Changes in calcium in response to a variety of different HIV-associated 
challenges reflect a gradual accumulation due to a dysregulation of calcium 
recovery.
• The gradual calcium increase precedes the development of structural pathology 
such as beading and is associated with a loss of actin structure and transport 
function.
• These pathological changes mimic early neuronal pathology for other 
neurodegenerative diseases potentially revealing a common underlying 
mechanism.
• The cellular pathology and calcium changes are reversed by the novel 
neurotrophin ligand, LM11A-31, providing a neurotrophin-based option for 
early intervention.
• These studies help to clarify the causes of neural damage induced by HIV 
infection and establish the p75 neurotrophin receptor as a valuable target for the 
treatment of HIV-associated neurodegeneration.
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Figure 1. 
Cell death and calcium changes induced by different subtypes of HIV-1 gp120 in primary 
rat mixed neural cultures. A. Neurons were treated with 200 pM gp120 for a period of 24 h. 
Cell death was assessed using ethidium homodimer to stain dead cell nuclei. The number of 
dead cells/mm2 was increased for all gp120 subtypes. Cell death ranged from 1.4 ± 0.2% of 
total neurons in the control cultures to a maximum of 6.5 ± 0.5% for gp120IIIB. Values 
represent the mean ± sem. * p<0.05 relative to control (One way ANOVA followed by 
individual paired comparisons, n=9). B. Co-incubation with 10 nM LM11A-31 prevented 
gp120-induced cell death in cultures treated with 200 pM gp120 or strong inflammatory 
stimulation with lipopolysaccharide (LPS, 0.1 μg/ml) and rat interferon-γ (INF, 20 U/ml 
LPS). *p<0.01 t-test, treatment vs. no treatment, (n=8).
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Figure 2. 
A. Incubation of neural cultures with CXCR4-preferring subtypes of gp120 (IIIB, MN) or 
CCR5-preferring subtypes (BaL, SF162) all provoked gradual increases in intracellular 
calcium (Fluorescence Increase). B. Chronic treatment of neural cultures with gp120 for 3 
days resulted in an increased calcium response to a 2 s pulse of glutamate. C. Fluorescence 
values (F) at each post-stimulation time point were normalized to the peak calcium (Fpeak) 
and then plotted as log F/Fpeak versus time to provide an estimate of the rate of recovery. A 
75–81% reduction in the rate of recovery of intracellular calcium was seen after exposure to 
gp120. D. The decrease in calcium recovery persisted when neurons were matched for acute 
calcium load (10 control, 10 gp120). Inset: An average decrease in recovery rate of 80% was 
seen with calcium load matched. Data points are mean ± sem (n=20–47 neurons from at 
least three independent studies).
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Figure 3. 
Rat neural cultures challenged with medium from human monocyte-derived macrophages 
(hMDM) treated for three days with 200 pM gp120IIIB or gp120BaL. A. The macrophage 
conditioned medium (MCM) was added at a dilution of 1:5 at 0 min and produced a large 
acute rise in intracellular calcium (Fluorescence Increase) followed by minimal recovery and 
a delayed destabilization of intracellular calcium. No difference was seen between medium 
from MCM treated with gp120IIIB (47 cells) or gp120BaL (30 cells). Medium collected from 
hMDM prior to treatment with gp120 (MCM-pretreat) produced a similar acute rise in 
intracellular calcium but only a small delayed rise (179 cells). Results represent 3–7 
independent experiments. B. Single example of the response to glutamate at the same 
concentration present in the MCM. A similar acute response was observed which rapidly 
recovered to baseline with no plateau or delayed rise.
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Figure 4. 
Neuronal damage induced by addition of a low density of rat MDM (rMDM, 1000 
cells/cm2) which were pre-treated for 24 h with 200 pM gp120IIIB and then labeled with DiI 
acetylated LDL. Neurons stained with MAP-2 (green) could be visualized in the same 
regions as the rMDM (red). A. With no rMDM nearby or in the absence of rMDM (not 
shown), the neurons displayed normal morphology. When localized next to rMDM neurons 
showed different levels of damage ranging from early signs of dendritic beading (B) to 
prominent dendritic beading with truncation of processes (C).
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Figure 5. 
The p75 neurotrophin receptor ligand, LM11A-31 protects neurons from toxicity induced by 
MCM. Loss of neuronal MAP-2 stain was measured as a percent of the total area after 
treatment with MCM at a dilution of 1:5. Loss of MAP-2 immunoreactivity (n=9) mainly 
reflected loss of processes and was reversed by concurrent treatment with 10 nM LM11A-31 
(n=13). *p<0.05 t-test, relative to vehicle-treated cells, ** p<0.05 t-test, relative to cells 
treated with MCM only.
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Figure 6. 
Neuronal damage produced by 24 h treatment with MCM (1:5) and reversal by LM11A-31. 
A. Addition of MCM to the neural cultures resulted in dendritic beading and thinning of 
neuronal processes. B. Co-treatment with 2 nM LM11A-31 partially reversed the beading 
and loss of processes. C. Co-treatment with 10 nM LM11A-31 reversed the pathology with 
extensive outgrowth of neuronal processes, indistinguishable from untreated cultures (not 
shown).
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Figure 7. 
Example of the calcium response of cultured rat neurons to MCM (1:5) or MCM + 
LM11A-31 (10 nM). Cells were loaded with Fluo-4 AM and the fluorescence intensity 
captured and pseudocolored with Metamorph software (white > red > yellow > green > blue 
> dark blue). Addition of MCM resulted in a large acute calcium response at 0.1 min which 
failed to recover by 3 min. After 60 min, the neurons were markedly swollen and the 
processes showed extensive beading. Neurons run in parallel and challenged with the MCM 
after pre-treatment with LM11A-31 for 10 min showed a comparable acute calcium 
response followed by substantial recovery by 3 min and no significant delayed calcium rise 
or pathology. The lower panels illustrate, at high magnification, the development of 
dendritic beading at 36 min after treatment of neurons with MCM. The beading is 
accompanied by small local increases in calcium (arrows).
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Figure 8. 
Reversal of delayed calcium destabilization by LM11A-31. A. Neurons were treated with 
MCM to generate an acute calcium rise and a delayed calcium destabilization (solid circles). 
Addition of 10 nM LM11A-31 to the cells 10 min prior to the addition of MCM did not 
affect the acute calcium response but accelerated calcium recovery and prevented the 
delayed destabilization. The extent of recovery was limited to 37.0% at 10 min in the MCM 
challenged cells while the cells pretreated with LM11A-31 showed 91.6% recovery (n=53 
neurons). Vehicle (aCSF, n=355) and gp120 (n=28) were run to establish basal calcium 
dynamics and to control for potential effects of residual gp120. Figures represent results 
from 4–7 independent experiments. The gp120 evoked a very small acute calcium rise 
followed by a slight upward drift in intracellular calcium that paralleled the basal calcium 
response. B. The rate of calcium recovery in neurons treated with MCM with and without 
LM11A-31 was estimated from the slope of the plot of the log of cell fluorescence at each 
time point (F) relative to the peak fluorescence (Fpeak). Neurons pretreated with LM11A-31 
had a 3-fold increase in the rate of recovery relative to cells treated with MCM alone. C. 
Conditioned medium from neural cultures treated with HIV gp120 induced an acute calcium 
response but failed to provoke a delayed destabilization of calcium. D. The number of large 
swellings (beading) in the processes was negligible in neurons treated with aCSF and 
slightly increased following incubation in macrophage conditioned medium collected prior 
to the challenge (MCM control). A large increase in swellings was seen after treatment with 
MCM which was prevented by concurrent treatment with 10 nM LM11A-31. * p=0.002 t-
test vs. MCM control, **p=0.023 t-test, vs. MCM.
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Figure 9. 
Neuronal staining for phospho-Akt (pAkt) green and MAP-2 (red) after 20 h treatment with 
MCM ± LM11A-31. In vehicle treated control neurons, pAkt was seen in the cytosol of 
MAP-2 stained neurons (A–C) and could also be seen as a weaker stain in astrocytes in the 
background. Treatment with macrophage conditioned medium (MCM) resulted in a small 
reduction in the pAkt stain intensity (D–F) which was prevented in the presence of 10 nM 
LM11A-31 (G–I). J. Quantification of the stain intensity from a total of 47–103 neurons 
sampled for each condition across 5 different experiments using an unbiased sample 
template. A two way analysis of variance showed a significant beneficial main effect of 
MCM + LM11A-31 relative to MCM (all p’s < 0.05) which was followed by individual 
paired comparisons. Four hours after treatment with MCM a 25.1% decrease in MAP-2 
immunoreactivity was seen (p=0.020) with a small but non-significant reversal by 10 nM 
LM11A-31. After 20 h, MAP-2 immunoreactivity was decreased by 28.7%. Co-treatment 
with 10 nM LM11A-31 completely prevented the loss (p<0.001). At 4 h post-treatment an 
increase in neuronal pAkt was seen under all conditions (p’s<0.001). By 20 h in MCM, a 
small significant decrease in pAkt expression of 15.6% was seen (p=0.002). In the presence 
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of MCM+LM11A-31, the expression of pAkt was maintained at a level significantly greater 
than both control and MCM treated neurons (+69.2 –100.5%, p’s<0.001).
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Figure 10. 
Neuronal staining for phospho-CREB (pCREB) green and MAP-2 (red) after 20 h treatment 
with MCM ± LM11A-31. In vehicle treated control neurons, pCREB (A) was preferentially 
localized to the nucleus of neurons (B, MAP-2) with smaller amounts in the cytosol. C. 
Merged images showing green nucleus in MAP-2 (red) stained neurons. D–F. Treatment 
with macrophage conditioned medium (MCM) resulted in a small reduction in the pCREB 
stain intensity and a loss of nuclear stain in slightly damaged cells (arrow, swollen neuron). 
The loss of pCREB was prevented in some neurons in the presence of 10 nM LM11A-31 (G, 
arrowhead) while others showed reduced staining in the nucleus (G, arrow) relative to the 
cytosol. H–I. MAP-2 intensity was increased by LM11A-31. J. Quantification of the stain 
intensity from a total of 60–83 neurons sampled for each condition across 5 different 
experiments using an unbiased sample template. A two way analysis of variance showed a 
significant beneficial main effect of MCM + LM11A-31 relative to MCM (all p’s < 0.05). 
Individual paired comparisons showed no significant change in neuronal pCREB at 4 h in 
MCM (+7.4%) or MCM+LM11A-31 (+14.0%). At 20 h post-stimulation, pCREB was 
decreased relative to untreated controls (−30.6%, p<0.001). Addition of 10 nM LM11A-31 
to the MCM partially prevented the loss of pCREB (−15.7% p<0.001, MCM+LM11A-31 vs. 
MCM).
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Figure 11. 
Time course for the development of mitochondrial depolarization and calcium accumulation 
in parallel neuronal cultures. Examples of two types of temporal calcium responses in 
regions of dendritic beading across at least triplicate runs are illustrated in A and B for cell 
40-1 and cell 59-2. The box indicates the time during which swelling develops. A. Local 
regions of dendritic swelling in some neurons exhibited small calcium spikes as early as 14 
min post-stimulation followed by a rapid increase (32 min) and swelling (48 min). B. The 
region of dendritic swelling in other neurons often showed a continuous accumulation of 
calcium beginning about 20 min prior to the development of swelling. C. Mitochondria were 
visualized with JC-1 (44 neurons) and neuronal calcium with Fluo-3 (224 neurons). The 
ratio of green fluorescence to red fluorescence in individual mitochondria within the 
neuronal cell body was measured to track changes in the mitochondrial membrane potential. 
Fluo-3 fluorescence intensity was used to track changes in intracellular calcium in matched 
parallel cultures. To facilitate comparison, fluorescence changes were normalized to the 
peak change and plotted together. Fluorescence ratios reflecting full mitochondrial 
depolarization were assessed by adding 1 μM FCCP at the end of the experiment. 
Destabilization of calcium appeared between 20–40 min, well before changes in the 
mitochondrial membrane potential. Values represent the mean ± sem.
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Figure 12. 
Comparison of regions of dendrite calcium accumulation and swelling to the location of 
mitochondria. A. Calcium changes were measured over time in neurons loaded with the 
indicator Fluo-4 (green). Dendrites with focal swellings were identified in the images, traced 
and the fluorescence intensity was measured and plotted over the length of the dendrite. B. 
Mitochondria were stained with 100 nM TMRM (red) for 10 minutes and imaged in the 
same fashion. C. Merging of the calcium and TMRM stains to show overlap. In some 
swellings mitochondria appeared to be misoriented (arrow) suggesting a disruption of 
normal movements. D. The plots of calcium increases (Fluo-4 fluorescence, solid circles) 
and mitochondrial stain (TMRM, open circles) were superimposed and compared to 
evaluate the co-localization of the two images. This example shows both overlapping and 
non-overlapping (arrow) signals from a single representative dendrite. Mitochondria were 
more abundant that the swellings and were present in many areas with no swelling. 
Conversely, swellings occasionally had mitochondria present but more typically showed no 
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TMRM stained mitochondria. E. Tomm20 stain (green) of fixed cells (97% methanol:3% 
acetic acid) showing mitochondria (green) superimposed on the MAP-2 stained (red) 
dendrite with prominent swellings (arrows). Overlapping regions appear yellow and often 
show clusters of mitochondria. Since these cells received the same treatment as A–C above 
the results indicated that the mitochondria are poorly visible with the membrane potential-
dependent stain TMRM. Mitochondria not associated with dendrites (green dots) can be 
seen in the background. F. The same positional mapping as above showed that almost all 
swellings (94.3%) contained mitochondria.
Meeker et al. Page 35
Exp Neurol. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 13. 
Accumulation of F-actin aggregates in neurons treated with MCM. A. Example of a 
dendritic swelling (box) containing a dense accumulation of F-actin stained with phalloidin-
Alexa488. B. At high magnification (boxed area in A), the actin appears as amorphous 
aggregates. Similar aggregates were seen in growth cones from MCM-treated cultures (D) 
relative to untreated cultures (C).
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Figure 14. 
Mitochondrial movements in neurons are decreased after treatment with MCM and restored 
by LM11A-31. To measure movements during the period of delayed destabilization of 
calcium, images were captured 20 min after addition of MCM. A. Successive movements of 
TMRM stained mitochondria were measured over 6 s intervals in 50 randomly selected 
mitochondria from normal (aCSF treated) cultures. The velocity of movement was plotted 
sequentially for each of 1157 epochs where the mitochondria could be clearly tracked. Peaks 
reflect periods of rapid movement interspersed with periods of slow or no movement. B. 
After addition of MCM there was a reduction in the number of rapid movements. C. The 
mean velocity of a total of 200 mitochondria sampled at 20 s intervals from four 
independent experiments was 0.98 ± 0.13 μm/min in control cultures and was reduced to 
0.47 ± 0.09 μm/min in cultures treated with MCM (p=0.002). Addition of 10 nM LM11A-31 
with the MCM preserved the movements of the mitochondria (1.10 ± μm/min, p=0.004 vs. 
MCM). D. The relative intensity of the TMRM, reflecting the mitochondrial membrane 
potential, did not change significantly over time in the MCM-treated cultured (<2%) and 
increased slightly (<3%) in MCM+LM11A-31 and control cultures. E. The average relative 
length of mitochondria decreased slightly in all conditions but no significant differences 
were seen between conditions.
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